797 related articles for article (PubMed ID: 16088807)
1. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
[TBL] [Abstract][Full Text] [Related]
3. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants.
Vesikari T; Karvonen A; Korhonen T; Espo M; Lebacq E; Forster J; Zepp F; Delem A; De Vos B
Vaccine; 2004 Jul; 22(21-22):2836-42. PubMed ID: 15246619
[TBL] [Abstract][Full Text] [Related]
5. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
[TBL] [Abstract][Full Text] [Related]
6. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada.
Dennehy PH;
Vaccine; 2006 May; 24(18):3780-1. PubMed ID: 16111790
[TBL] [Abstract][Full Text] [Related]
7. A short report on highlights of worldwide development of RIX4414: a Singaporean experience.
Phua KB; Quak SH; Emmanuel S; Goh PS; Han HH; Hardt K; Bock HL; De Vos B
Vaccine; 2006 May; 24(18):3782-3. PubMed ID: 16600443
[TBL] [Abstract][Full Text] [Related]
8. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B
Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
10. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability.
Cheuvart B; Friedland LR; Abu-Elyazeed R; Han HH; Guerra Y; Verstraeten T
Pediatr Infect Dis J; 2009 Mar; 28(3):225-32. PubMed ID: 19209095
[TBL] [Abstract][Full Text] [Related]
11. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.
Steele AD; De Vos B; Tumbo J; Reynders J; Scholtz F; Bos P; de Beer MC; Van der Merwe CF; Delem A
Vaccine; 2010 Sep; 28(39):6542-8. PubMed ID: 18786585
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
[TBL] [Abstract][Full Text] [Related]
13. A short report on highlights of world-wide development of RIX4414: a Latin American experience.
Linhares AC; Ruiz-Palacios GM; Guerrero ML; Salinas B; Perez-Schael I; Clemens SA; Innis B; Yarzabal JP; Vespa G; Cervantes Y; Hardt K; De Vos B
Vaccine; 2006 May; 24(18):3784-5. PubMed ID: 16098636
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Salinas B; Pérez Schael I; Linhares AC; Ruiz Palacios GM; Guerrero ML; Yarzábal JP; Cervantes Y; Costa Clemens S; Damaso S; Hardt K; De Vos B
Pediatr Infect Dis J; 2005 Sep; 24(9):807-16. PubMed ID: 16148848
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
[TBL] [Abstract][Full Text] [Related]
17. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
[TBL] [Abstract][Full Text] [Related]
18. Lack of shedding of the RIX4414 live attenuated rotavirus vaccine administered to adult volunteers.
Zibrik L; Dove W; McArdle F; Rustom R; Hart CA; Jackson MJ
Arch Virol; 2007; 152(10):1951-4. PubMed ID: 17623269
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.
Bhandari N; Sharma P; Taneja S; Kumar T; Rongsen-Chandola T; Appaiahgari MB; Mishra A; Singh S; Vrati S;
J Infect Dis; 2009 Aug; 200(3):421-9. PubMed ID: 19545211
[TBL] [Abstract][Full Text] [Related]
20. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age.
Zaman K; Sack DA; Yunus M; Arifeen SE; Podder G; Azim T; Luby S; Breiman RF; Neuzil K; Datta SK; Delem A; Suryakiran PV; Bock HL;
Vaccine; 2009 Feb; 27(9):1333-9. PubMed ID: 19162114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
